Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Medicare Wastage ‘Refund’ Collections Delayed To ‘Align’ With IRA

Executive Summary

A new Medicare rebate for discarded portions of single-use vials is taking effect as scheduled in January – but the first invoices won’t be issued in the fall as planned. CMS says it wants to wait to ‘align’ the collections process with the new inflation rebates enacted by the IRA.

You may also be interested in...

Medicare Needs ‘Robust’ Claims Oversight So Inflation Rebates Won’t Duplicate 340B Discounts

PhRMA urges CMS to take a more proactive approach to monitoring 340B claims than previously proposed. Meanwhile, hospitals object to the claims modifier requirement.

Medicare Wastage Rebate Exceptions For Small Volume Products, Cell/Gene Therapy Urged

Packaging for such products reflects ‘unique circumstances’ that should exempt them from the rebates on discarded drugs otherwise required by the policy, stakeholders tell CMS at a ‘town hall’ forum.

Medicare ASP Reporting: CMS Weighing Guidance, Beefed Up Internal Controls To Ensure Accuracy

US Health and Human Services Department Inspector General issues two reports on manufacturer-reported average sales prices and how their accuracy could be improved. ASPs serve as the basis for Medicare Part B reimbursement and will also be used to guide implementation of price inflation-based rebate penalties for Part B drugs beginning in the first quarter of 2023.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts